Page last updated: 2024-12-11

ono 4057

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ONO-LB 457: LTB4 receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438358
CHEMBL ID422420
SCHEMBL ID119003
MeSH IDM0185042

Synonyms (22)

Synonym
CHEMBL422420 ,
5-{2-(2-carboxy-ethyl)-3-[(e)-6-(4-methoxy-phenyl)-hex-5-enyloxy]-phenoxy}-pentanoic acid
bdbm50037382
5-{2-(2-carboxy-ethyl)-3-[6-(4-methoxy-phenyl)-hex-5-enyloxy]-phenoxy}-pentanoic acid (ono-4057)
benzenepropanoic acid, 2-(4-carboxybutoxy)-6-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-, (e)-
5-(2-(2-carboxyethyl)-3-(6-(4-methoxyphenyl)-5e-hexenyl)oxyphenoxy)valeric acid
ono-lb 457
ono 4057
ono-lb-457
134578-96-4
ono-4057
5-[2-(2-carboxyethyl)-3-[(e)-6-(4-methoxyphenyl)hex-5-enoxy]phenoxy]pentanoic acid
gtpl6157
SCHEMBL119003
CS-7440
HY-U00252
ono4057
(e)-5-(2-(2-carboxyethyl)-3-((6-(4-methoxyphenyl)hex-5-en-1-yl)oxy)phenoxy)pentanoic acid
Q27088186
DTXSID201124899
2-(4-carboxybutoxy)-6-[[(5e)-6-(4-methoxyphenyl)-5-hexen-1-yl]oxy]benzenepropanoic acid
AKOS040742340
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene B4 receptor 1Homo sapiens (human)Ki0.00390.00010.51267.0000AID102633; AID102635; AID102640
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
muscle contractionLeukotriene B4 receptor 1Homo sapiens (human)
inflammatory responseLeukotriene B4 receptor 1Homo sapiens (human)
immune responseLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
neuropeptide signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nucleotide bindingLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene B4 receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID102640Compound was tested for inhibitory activity against human neutrophil LTB4 receptor binding1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID76807Compound was tested in vivo inhibitory activity against LTB4 induced neutrophil influx in guinea pig(orally)1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID91165Compound was tested in vitro inhibitory activity against human neutrophil degranulation.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID102635Binding affinity at leukotriene B4 receptor on intact human PMNs by displacement of [3H]LTB4.1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
AID102633Binding affinity against LTB4 receptors in human PMNs using [3H]LTB4 as radioligand1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
AID76805Compound was tested in vivo inhibitory activity against LTB4 induced neutropenia in guinea pig.(orally)1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID1346072Human BLT1 receptor (Leukotriene receptors)1992Prostaglandins, Oct, Volume: 44, Issue:4
ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's32 (64.00)18.2507
2000's14 (28.00)29.6817
2010's3 (6.00)24.3611
2020's1 (2.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.24 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.00%)5.53%
Reviews2 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (94.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]